NCT06439563 - Study to Evaluate the Efficacy and Safety of JP-1366 in the Prevention of NSAIDs-Induced Peptic Ulcers | Biotech Hunter

Enrollment

364

Participants

Timeline

Start Date

October 22, 2024

Primary Completion Date

August 31, 2027

Study Completion Date

December 31, 2027

Conditions

Peptic Ulcer

Interventions

DRUG

JP-1366 10 mg

JP-1366 10 mg, tablet, orally once a day for up to 24 weeks

DRUG

Lanston Capsule 15 mg

Lanston Capsule 15 mg orally once a day for up to 24 weeks

DRUG

JP-1366 10 mg placebo

JP-1366 10 mg placebo, tablet, orally once a day for up to 24 weeks

DRUG

Lanston Capsule 15 mg placebo

Lanston Capsule 15 mg placebo, orally once a day for up to 24 weeks

Trial Locations (1)

RECRUITING

Konkuk University Medical Center, Seoul